Rasha Cosman

机构：New South Wales Department of Health, Garvan Institute of Medical Research, UNSW Sydney, St Vincent's Hospital Melbourne, St Vincent's Hospital Sydney, St Vincent’s Private Hospital Sydney, The Kinghorn Cancer Centre · ORCID：0000-0002-4746-0747

发表论文 85 篇 · 总被引 579 次 · h-index 13

代表论文

• Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study (2025 · Journal of Clinical Oncology · 被引 28)
• 916O Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors (2025 · Annals of Oncology · 被引 10)
• Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations (2025 · Clinical Cancer Research · 被引 7)
• Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study (2026 · Nature Communications · 被引 6)
• Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC). (2026 · Journal of Clinical Oncology · 被引 5)
• 1342 First-in-human dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and initial efficacy of mRNA-LNP MT-302 in vivo CAR therapy in solid tumors (2025 · 被引 4)